FDA scientists push back on interim green light for unapproved peptides

The peptide wars have entered a new phase. The Washington Post reported October 7 that federal health officials are preparing a stopgap order — interim enforcement discretion — that would let state-licensed compounding pharmacies dispense certain restricted peptides with a prescription before the FDA finishes writing formal rules. One day later, FDA career scientists pushed back publicly: drug-center staff told reporters they could not recommend the interim dispensing order, citing the lack of safety and efficacy evidence.

What would the stopgap actually do?

At issue is a regulatory limbo: several peptides sit in a gray zone — restricted but not formally ruled on — while the FDA writes the regulations that would settle their status. The reported stopgap would bridge that gap by telling the agency's enforcers to look the other way, in the interim, when licensed compounders dispense certain of these peptides with a valid prescription. The plan is not yet official, and its scope and timing are unclear.

Why are FDA scientists objecting?

The objection from FDA's own drug center is the story's core. Career staff told the July advisory panel — and reporters this week — that they could not recommend compounding these peptides because the safety and efficacy evidence does not exist. An advisory vote to allow compounding is not an approval; it is a procedural judgment. The staff position is that patients would be the experiment.

Where do mitochondria fit in?

This site has tracked the mitochondrial side of this fight for months: the FDA's warning letters that named the mitochondria-targeting peptide SS-31, the BPC-157 evidence record (209 studies, zero human trials), and the July vote that cleared six peptides — including the mitochondrial peptide MOTS-c — for compounding consideration. The interim order would touch exactly this class of products: compounds with real biological intrigue and unproven human safety.

What to watch next

Watch for three things: whether the order is actually issued and which peptides it names; whether the FDA's formal rulemaking contradicts the interim policy; and whether adverse-event reports follow wider availability. The pattern of this year — the Greenwich glutathione recall, the compounding crackdowns — suggests the quality risks of gray-market peptides are not theoretical. We will keep tracking it.

Where the evidence stands

• Established: The reported positions are documented: the Washington Post reported the planned stopgap (Oct 7); Citeline's Pink Sheet reported FDA drug-center staff opposition (Oct 8); FDA advisers voted on six peptides in July without establishing safety or efficacy.
• Contested: Whether and when the interim order issues, which peptides it covers, and the underlying safety evidence for the affected compounds — all unresolved.